Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,099 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Kim DY, Lee JH, Lee JH, Lee KH, Kim YK, Ahn JS, Kim HJ, Kim I, Yoon SS, Park S, Bae SH, Bang SM, Lee HG, Shin HJ, Lee JH, Min YH, Won JH, Mun YC, Oh D; Korean Society of Hematology AML/MDS Working Party. Kim DY, et al. Among authors: kim yk, kim hj, kim i. Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19. Ann Hematol. 2010. PMID: 19543727
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim HJ, Kim YK, Park JS, Jeong SH, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Mauro MJ, Kim DW. Lee SE, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim sh, kim dy, kim ja. Am J Hematol. 2013 Jun;88(6):449-54. doi: 10.1002/ajh.23427. Epub 2013 Mar 28. Am J Hematol. 2013. PMID: 23440689 Free article.
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
Lee SM, Lee WS, Shin HJ, Lee JJ, Sohn SK, Moon JH, Eom HS, Won JH, Lee KH, Lee JH, Kim DY, Yoon SS, Kim I, Jung CW, Kim SJ, Kim H, Lee JH, Ryoo HM, Lee GW, Kim SH, Mun YC, Kim MK, Joo YD; Korean Society of Hematology Adult ALL working party. Lee SM, et al. Among authors: kim h, kim dy, kim sh, kim sj, kim i, kim mk. Ann Hematol. 2013 Aug;92(8):1101-10. doi: 10.1007/s00277-013-1728-y. Epub 2013 Apr 5. Ann Hematol. 2013. PMID: 23558905 Clinical Trial.
Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes.
Kim Y, Kim IH, Kim HJ, Park S, Lee KH, Kim SJ, Lee JH, Kim DY, Yoon SS, Kim YK, Jang JH, Park SY, Ahn JS, Cheong CW, Lee JH, Cheong JW; Korean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party. Kim Y, et al. Among authors: kim ih, kim hj, kim yk, kim dy, kim sj. Int J Hematol. 2014;99(5):635-43. doi: 10.1007/s12185-014-1549-3. Epub 2014 Mar 20. Int J Hematol. 2014. PMID: 24648120
Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.
Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, Kim YK, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Park JS, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim sh, kim dy, kim ja. Leuk Lymphoma. 2016 Feb;57(2):341-347. doi: 10.3109/10428194.2015.1049166. Epub 2015 Jun 12. Leuk Lymphoma. 2016. PMID: 25947037
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Kim DY, et al. Among authors: kim sd, kim h, kim dh, kim ys, kim i, kim kh, kim k. Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11. Blood. 2015. PMID: 26065651 Free article. Clinical Trial.
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lim SN, Joo YD, Lee KH, Kim DY, Lee JH, Lee JH, Chi HS, Yun SC, Lee WS, Lee SM, Park S, Kim I, Sohn SK, Moon JH, Ryoo HM, Bae SH, Hyun MS, Kim MK, Kim HJ, Yang DH, Eom HS, Lee GW, Jung CW, Won JH, Kim H, Lee JH, Shin HJ, Jang DY. Lim SN, et al. Among authors: kim h, kim hj, kim dy, kim i, kim mk. Am J Hematol. 2015 Nov;90(11):1013-20. doi: 10.1002/ajh.24137. Epub 2015 Oct 12. Am J Hematol. 2015. PMID: 26228525 Free article. Clinical Trial.
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW. Lee SE, et al. Among authors: kim h, kim hj, kim dw, kim sh, kim dy, kim ja. Haematologica. 2016 Jun;101(6):717-23. doi: 10.3324/haematol.2015.139899. Epub 2016 Feb 17. Haematologica. 2016. PMID: 26888022 Free PMC article.
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW. Kwak JY, et al. Among authors: kim h, kim hj, kim dw, kim sh, kim dy, kim ja. Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939746 Clinical Trial.
5,099 results